Associated Genetic Biomarkers
Peroxisome proliferator-activated receptor gamma (PPARG) is a gene that encodes a protein that functions as a nuclear receptor. The protein also regulates adipocyte differentiation. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer.
PPARG is altered in 1.01% of all cancers with bladder urothelial carcinoma, cutaneous melanoma, lung adenocarcinoma, melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PPARG are PPARG Amplification (0.22%), PPARG S186fs (0.03%), PPARG T475M (0.04%), PPARG Loss (0.03%), and PPARG E79K (0.02%) .
PPARG status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains PPARG status as an inclusion criterion, 1 is phase 2 (0 open).
The most frequent alteration to serve as an inclusion eligibility criterion is PAX8-PPARG Fusion .
Significance of PPARG in Diseases
Thyroid Gland Carcinoma +
PPARG is altered in 0.25% of thyroid gland carcinoma patients .
PPARG is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPARG status and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.